TRIUMPH Trial Stops Recruiting: What the Phase 3 Retatrutide Study Closing Enrollment Means for Patients

April 17, 2026  ·  6 min read

What Does It Mean That the TRIUMPH Trial Has Stopped Enrolling?

On April 17, 2026, the TRIUMPH retatrutide Phase 3 trial — formally titled A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight — quietly closed enrollment on ClinicalTrials.gov. For the thousands of patients and clinicians following the retatrutide story, this update is meaningful — and for most people, it is actually a signal of progress rather than a setback.

Closing enrollment simply means the study has reached its target number of participants and is no longer accepting new volunteers. Patients already enrolled continue receiving treatment and completing their scheduled visits as planned. In plain terms: the trial is running on schedule, the patient population is locked in, and Eli Lilly is now focused on collecting the outcome data needed to support a regulatory submission.

This is a normal — and expected — milestone in the lifecycle of a Phase 3 obesity drug trial.

When Is the TRIUMPH Trial Expected to Complete, and What Happens Next?

According to the ClinicalTrials.gov listing, the primary completion date for NCT07232719 is listed as July 2027. Primary completion refers to the date by which the primary outcome measure data collection finishes — not the date the trial fully wraps up or the date a drug becomes commercially available.

Following primary completion, Eli Lilly would need to compile, analyze, and submit a New Drug Application (NDA) to the FDA. As of April 2026, no NDA has been filed for retatrutide, and the FDA approval timeline has not been publicly confirmed. Regulatory review typically takes twelve months or longer after NDA submission, though priority review designations can shorten that window.

The broader TRIUMPH program already has meaningful Phase 3 data in hand. The TRIUMPH-4 trial — a 68-week Phase 3 study — reported a mean weight loss of 28.7% at the 12mg dose, representing the highest mean weight loss ever recorded in a Phase 3 obesity clinical trial. That figure was disclosed in an Eli Lilly press release dated December 11, 2025. Peer-reviewed publication of TRIUMPH-4 data was still pending as of April 2026.

Does the Trial Closing Enrollment Affect My Chances of Getting Retatrutide?

For patients who were not already enrolled, the short answer is: the trial closing enrollment does not reduce access to retatrutide upon eventual FDA approval. Trial participation and commercial availability are entirely separate pathways. Most patients will access retatrutide through a licensed prescriber once — and if — it receives FDA approval, not through a clinical trial.

What the enrollment closure does mean is that the window for joining this particular study as a research participant has closed. Patients who had hoped to receive retatrutide through the trial itself will need to wait for the commercial pathway.

What Is Retatrutide (LY3437943) and Why Is the TRIUMPH Trial Important?

Retatrutide, developed by Eli Lilly under the compound name LY3437943, is a triple hormone receptor agonist — meaning it simultaneously activates the GLP-1, GIP, and glucagon receptors. This triple mechanism distinguishes it from existing approved therapies. GLP-1 receptor agonism reduces appetite and slows gastric emptying. GIP receptor agonism appears to enhance the metabolic and weight-loss effects of GLP-1. Glucagon receptor agonism increases energy expenditure — a meaningful addition that neither semaglutide nor tirzepatide provides.

In patient communities, retatrutide is commonly referred to as reta. Many patients who follow obesity medicine closely describe a dramatic reduction in what is often called food noise — the persistent, intrusive mental preoccupation with food that drives overconsumption and makes sustained behavior change so difficult. The triple agonist mechanism of retatrutide appears to address food noise through multiple complementary pathways.

To understand what makes the TRIUMPH trial data so significant, a comparison to existing Phase 3 obesity trials is helpful:

Drug	Mechanism	Trial	Duration	Mean Weight Loss (Top Dose)
Semaglutide 2.4mg	GLP-1 agonist	STEP-1	68 weeks	~14.9%
Tirzepatide 15mg	GLP-1 / GIP dual agonist	SURMOUNT-1	72 weeks	20.9%
Retatrutide 12mg	GLP-1 / GIP / glucagon triple agonist	TRIUMPH-4	68 weeks	28.7%

The Phase 2 data, published in the New England Journal of Medicine in 2023, also documented meaningful improvements in cardiometabolic markers. At 24 weeks, the 12mg dose was associated with a 34.0% reduction in fasting triglycerides and a 17.3% reduction in total cholesterol. Quality of life scores, measured by the SF-36v2, improved across all active dose groups at week 48.

Tolerability data from TRIUMPH-4 showed that dysesthesia — an unusual skin sensation — occurred in 20.9% of participants receiving the 12mg dose versus 0.7% on placebo. Discontinuation rates were 18.2% in the 12mg group compared to 4.0% on placebo, with some discontinuations attributed to what investigators described as perceived excessive weight loss. These are important data points for patients and prescribers to discuss during shared decision-making.

How Do I Get Access to Retatrutide When It Becomes Available?

There is no approved commercial formulation of retatrutide available in the United States as of April 2026, and no NDA has been filed with the FDA. Patients should be cautious of any source claiming otherwise.

The legitimate pathway forward involves staying informed, working with a qualified obesity medicine specialist, and ensuring that when retatrutide does become available, there is already an established clinical relationship in place. Retatrutide will require physician evaluation, appropriate patient selection, careful titration — the TRIUMPH-4 protocol escalated from 2mg through 4mg, 6mg, 9mg, and finally 12mg over the first 16 weeks — and ongoing monitoring for adverse effects and metabolic response.

Patients who want to stay ahead of the curve should consider joining the glp3md waitlist now. No promises can be made about treatment outcomes or medication availability — retatrutide has not yet received FDA approval and no NDA has been filed. The waitlist is simply a way to stay informed and be among the first to know when access becomes possible. Visit https://www.glp3md.com to join.

This article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.